Since CD2, CD3D, CD3E, and CXCR6 predict very favorable prognosis in CSCC, we evaluated the association of this new signature at transcriptomic level with the presence of tumor-infiltrating immune cell populations in CSCC. The gene discussed is CD3D; the disease is neoplasm.